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Editorial on the Research Topic
E3 Ubiquitin Ligases: From Structure to Physiology
Protein ubiquitination has emerged as a central regulatory mechanism of eukaryotic cells that
affects multiple cellular processes and is critical for timely protein degradation and signal
transduction. The topological nature of the assembled ubiquitin chain largely dictates the function
of the ubiquitinated protein and the cellular outcome. The molecules responsible for the post-
translational modification of protein substrates with ubiquitin comprise E1 ubiquitin-activating, E2
ubiquitin-conjugating, and E3 ubiquitin ligating enzymes. While deubiquitinating (DUB) enzymes
which remove ubiquitin chains have received a lot of attention, especially in the field of drug
discovery where some DUB inhibitors are approaching clinical trials, E3 ubiquitin ligases are only
recently coming into the limelight.
Despite impressive advances in the structural to physiological understanding of E3 ubiquitin
ligases, important aspects of E3s structure to function remain obscure. Undoubtedly, an enhanced
knowledge of the conformational dynamics, macromolecular interactions, and functional
integration of E3 ligases into cellular pathways will illuminate the precise roles of E3 ligases
in aberrant signaling processes. This will pave the way toward rationally manipulating these
enzymes for therapeutic intervention in many diseases that represent important health and
societal challenges. Targeted protein degradation has emerged as a powerful approach for the
removal of proteins driving human diseases. Amongst these, PROTACs, LYTACs, and AUTACs are
technologies that harness the endogenous protein ubiquitination machinery and target proteins for
degradation by the proteasome, lysosome, or through autophagy (Sakamoto et al., 2001; Takahashi
et al., 2019; Banik et al., 2020). Given these recent advances, a more detailed understanding of E3
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ubiquitin ligase functions and their modes of action are
paramount in order to fully exploit these endogenous cellular
waste recycling plants to improve human health.
The contributors to this Topic discuss how the integration of
cellular, chemical, biophysical, and structural biology methods
with “omics” approaches have clarified important aspects of E3
ubiquitin ligases activity, function, and mode of regulation. Such
insights include the mode of cooperation of E3s with other
enzymes for ubiquitin chain initiation and elongation, the precise
positioning of the donor and acceptor ubiquitin sites, and the
principles underpinning substrate-assisted catalysis. The subtle
mechanistic and ligand-recognition variations that are inscribed
in a spatial and temporal framework, confer these enzymes
with great substrate selectivity and specificity. Excitingly, all
the families of E3 ubiquitin ligases, including Really interesting
Genes (RING), HECTs (Homologous to the E6AP carboxyl
terminus), and RING-in between-RING, are represented in this
Research Topic. We would also like to bring to the attention of
readers, the Frontiers in Chemistry Research Topic on “Probing
the Ubiquitin Landscape” which focus on new chemical biology
tools and techniques to further dissect the role of protein
ubiquitination (Mulder et al., 2020).
Progressing from E3 ligases structure to physiology, Deol
et al. summarize our current understanding of the key molecular
principles of ubiquitin chain assembly and discuss current
evidence that supports two alternative, mechanistic models of
polyubiquitylation: a “sequential addition” model wherein one
ubiquitin unit is transferred at a time to a growing substrate-
linked ubiquitin and an “en bloc” model in which ubiquitin units
are assembled prior to their transfer onto a substrate. They also
discuss how the weak and dynamic nature of the interactions
represents a challenge to establish the trajectory of the functional
enzyme-substrate complexes.
Weber et al. review HECT-containing E3 ligases and explain
the reasons manipulating their catalytic activity is challenging
include their transient interactions and low binding affinities with
their substrates, as well as the redundancy among E3 ligases,
where depending on the cellular context, a specific substrate
may be modulated by several E3s. They argue that although
the high conservation of the HECT domain within the HECT
family means it may be difficult to develop specific inhibitory
compounds, a greater understanding of the structural features
and the underlying ubiquitination mechanisms used by different
HECT E3 ligases remains an important biological question
with the potential to unveil new opportunities for therapeutic
intervention. Mayor and collaborators investigate the HECT
ubiquitin ligase, UBE3A. Mutations in Ube3a cause Angelman
and Prader-Willi syndromes (Wheeler et al., 2017; Harris and
Stafford, 2020), both of which have no cure. Elu et al. identified
the UBE3A-dependent ubiquitination sites and ubiquitin chain
types formed on DDI1, a proteasome receptor. This contribution
is an important step toward the full characterization of the
UBE3A-dependent ubiquitination pathway that provides new
insight into the molecular basis of rare neurological disorders.
Some of the most poorly understood E3 ligases are the HERCs
(homologous to the E6AP carboxyl terminus and regulator of
chromosome condensation 1 (RCC1)-like domain-containing
proteins), which are divided into large and small subfamilies.
García-Cano et al. describe the high structural complexity of
large-HERC family members and their important functions
in diverse physiological processes, including cell proliferation,
neuronal development, DNA repair, and inflammation. They also
discuss the ways in which dysregulation of large-HERC ubiquitin
ligases can lead to neurological disorders and cancer.
Mdm2 and its homolog MdmX (also known as Mdm4)
are two RING E3 ubiquitin ligases that exert oncogenic
activity. A precise understanding of the nature of Mdm2-
MdmX interactions can be critical to exploiting them as
potential therapeutic targets for reactivation of p53 function in
tumors. Kosztyu et al. report a systematic mutational analysis
of human Mdm2 that included the exchange of segments of
its RING domain with the corresponding MdmX regions in
order to identify the molecular features that determine their
differential ability to forms dimers. Interestingly, the Mdm2
single substitution C449N blocked the ability of this protein
to form a heterodimer with MdmX, but it did not disrupt
Mdm2 RING self-association to form homodimers. Taken
together, the studies suggest that the effect of certain conserved
amino acid residues on Mdm2 homodimers and Mdm2-MdmX
heterodimers formation is context-specific and possibly not
entirely structurally equivalent. In contrast to HECT ligases,
RING E3s do not have intrinsic catalytic activity per se and
instead rely on adaptor molecules for the recruitment of substrate
proteins (Deshaies and Joazeiro, 2009). Rathje et al. report
an unanticipated function of Fbxo7, the substrate-recognition
subunit of an SCF-type ubiquitin E3 ligase complex, in male
germ cell cytoplasmic remodeling. They show that Fbxo7-
deficient male mice were completely sterile despite successful
meiosis, nuclear elongation and exclusion of histones from
chromatin. At the same time, Fbxo7 mutant mice exhibited a
sterility phenotype that has not been described before, where
total death and phagocytosis of all condensing spermatids
occurred in the absence of typical hallmarks of spermatid
apoptosis. A previous, independent report on the fruit fly
Fbxo7 ortholog nutcracker (ntc) shown to cause sterility at a
similar stage of germ cell development, indicates a conserved
requirement for Fbxo7 across species. The Fbxo7 mutant mice
represent a valuable new animal model for the study of late
spermiogenic, cell and tissue remodeling, and phagocytic events
in germ cell development. Yoshida et al. focus their review
on lectin-type F-box proteins, which recognize cytosolic sugar
chains as markers of unwanted proteins and organelles that
mediate aberrant or harmful signals and trigger ubiquitination,
thus ensuring homeostasis. They concluded that elucidation
of the molecular mechanisms underlying induction of sugar-
recognizing F-box proteins and promotion of SCF complex
formation by various stimuli is crucial for a deeper understanding
of F-box proteins functions and of cytosolic sugar chains. The
RING family of E3 ligases includes over 600 enzymes clustered
into TRIM, UBR and cullin-RING ligases. Zanchetta and Meroni
discuss MID1 and MID2, two members of the TRIpartite
Motif (TRIM) family of RING E3 ligases, the overexpression
of which is associated with lung adenocarcinoma, prostate and
breast cancer. They review the emerging evidence supporting
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the involvement of MID1 and MID2 in the regulation of
cytokinesis through MID1/MAD2 dynamic association with the
proteins Astrin, BRAF35, and PP2A and how defects in the
assembly of these complexes impairs cytokinesis, leading to
severe adverse outcomes, including embryo development defects
and cancer.
Approximately 50% of cancer patients receive treatment
with ionizing radiation (radiotherapy) at some point during
their cancer treatment. Fouad et al. present an analysis of
how radiotherapy efficacy could be improved in combination
with small size drugs that regulate the ubiquitin-proteasome
system (UPS), some of which are currently undergoing clinical
trials. The cullin family of E3 ligases is involved in several
pathways of immune responses which can be exploited to
modulate localized radiotherapy to induce out-of-target anti-
tumor effects leading to tumor regression at non-irradiated
metastatic sites, a phenomenon known as the abscopal effect.
Fouad et al. go one step further and discuss the therapeutic
approaches to target CRLs that have potential use in the
clinic, including proteolysis targeting chimeras (PROTACs)
of CRL adaptors that are only activated upon ionizing
radiation or under a specific stimulus that mimic the tumor’s
microenvironment such as hypoxia that ultimately aim to
improve patient survival.
Lescouzères and Bomont review the role of the Cullin
3-RING E3 ligase Gigaxonin in neurological diseases.
Gigaxonin mutation are most commonly associated with
Giant Axonal Neuropathies (GAN), a rare neurodegenerative
disease which in the most severe cases has a fatal outcome
usually before the third decade. Phenotypically, GAN
results in enlarged axons which are filled with abnormal
neurofilaments. The authors provide a comprehensive
review of the roles and functions of Gigaxonin, including
its known substrates, in cytoskeleton architecture, signal
transduction through Hedgehog signaling and autophagosome
production. The diversity in terms of substrates and cellular
processes regulated by Gigaxonin further emphasizes the
challenges associated with assigning a specific mechanism as
disease-causing which currently limits the development of
new therapies.
The RING-in between-RING (RBR) type of E3 ubiquitin
ligases ubiquitinate substrates via a RING-HECT hybrid manner,
and there are 14 RBR ligases known in humans. Lawrence
et al. discuss about one of the RBR ligases, Natural Killer
Lytic-Associated Molecule (NKLAM)/RNF19B in the regulation
of innate immunity. NKLAM was originally identified by the
authors as an IFNβ-induced gene in a human natural killer cell
line. NKLAM regulates immune signaling cascades of STAT and
NF-κB in immune cells, thus regulating cytokine production.
Through its important roles of NKLAM in immunity, NKLAM
shows anti-tumor function in vivo. More recent studies revealed
that NKLAM regulates not only immunity, but also autophagy
and responses to ER stress. The role of the ubiquitin ligase activity
of NKLAM in innate immunity or other biological functions is
yet to be discovered.
Finally, Escobar-Henriques and Joaquim discuss the role
of E3 ubiquitin ligases in the regulation of mitochondrial
quality control pathways. Mitochondria are highly dynamic
organelles that constantly undergo anchoring, fission, transport,
and membrane fusion. The latter process involves membrane
remodeling in which the highly conserved proteins mitofusins
(MFN1 and MFN2 in mammals and Fzo1 in yeast) play a central
role. The authors review the ubiquitin E3 ligases that modify
mitofusins in response to a variety of cellular inputs. They focus
their analysis on the mitochondrial RING E3 ubiquitin ligases
March5 and Mul1; Gp78, a ligase associated to the ER; and the
cytosolic enzymes the RING MGRN1, the HECT ligase HUWE1
and the RBR E3 Parkin, all of which ubiquitylate mitofusins.
The elucidation of molecular details underpinning mitofusins’
modifications by E3 ligases should pave the way to develop new
therapeutic approaches for the treatment of neurodegenerative,
cardiovascular and obesity-associated disorders. The authors
also provide novel insights on the roles of ubiquitin-dependent
mechanisms in the regulation of inter-organelle membrane
contact sites, a field which is revolutionizing our view of organelle
biology (Scorrano et al., 2019).
In summary, this Research Topic highlights important
discoveries in the structure to physiology understanding of E3
ubiquitin ligases, setting the stage to address important yet
unanswered questions in the ubiquitin signaling field. These
include the determination of the 3D structure of full length
E3 ubiquitin ligases, which is now achievable, as the cryo-EM
structure of the HECT ligase HUWE1 has shown (Hunkeler
et al., 2020); the definition of the entire human ubiquitome; the
mechanisms underlying substrate recognition and processing;
the regulation of protein ubiquitination in time and space
and tissue; the molecular basis for how deregulation of E3
ubiquitin ligases lead to disease. Addressing these questions will
be instrumental in order to develop innovative therapeutics.
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